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Identity 
Other names: HHG, LCGR, LGR2, LH/CGR, LHR, 
LHRHR, LSH-R, ULG5 
HGNC (Hugo): LHCGR 
Location: 2p16.3 
Note: The LHR belongs to the glycoprotein hormone 
receptor subfamily of the G protein-coupled receptor 
family (GPCR), with leucine rich repeat motifs, 
(Minegishi et al., 1990; Jia et al., 1991). 
DNA/RNA 
Description 
Human LHR gene is encoded by a single copy gene. 
The human LHR gene (> 80 Kb) consists of 11 coding 
exons separated by 10 introns (Atger et al., 1995). At 
least seven alternatively spliced variants of the hLHR 
were reported (deletion of exon 8 or 9 or 10, or partial 
deletion of exon 11 combined with or without deletion 
of exon 9, and insertion of exon 6A) (Laue et al., 1996; 
Gromoll et al., 2000; Madhra et al., 2004; Kossack et 
al., 2008). 
Transcription 
Multiple LHR mRNA transcriptional start sites are 
located within the -176 bp TATA-less 5' flanking 
promoter domain (Geng et al., 1999; Dufau and Tsai-
Morris, 2007).  
Additional upstream transcriptional start sites (> -176 
bp) were identified in human testicular mRNA and 
human choriocarcinoma JAR cell. EREhs (-161 to -171 
bp) and upstream sequences (-177 to -2056 bp) are 
inhibitory.  
Activation of the human LHR promoter through Sp1 
and Sp3 factors at Sp1 sites is negatively regulated by 
cross-talk among the transcription factors 
EAR3/COUP-TFI, Sp1, TFIIB, and independently by 
histone deacetylase-mSin3A co-repressor complex, 
p107 repressor at the Sp1 I site (review: Zhang and 
Dufau, 2004; Dufau and Tsai-Morris, 2007; Dufau et 
al., 2010). 
Pseudogene 
No known pseudogenes. 
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A: Human LHR gene organization. B: 5' flanking regu latory domains and the 176 bp promoter with its fun ctional domains  (Geng 
et al., 1999; Dufau and Tsai-Morris, 2007). B-I Promoter associated transcription factor Sp1 bound to cognate DNA sites, Sp1-I and Sp1-
II, constitutively (Geng et al., 1999). Co-repressor complex (HDAC/mSin3A) associates with Sp1-I (Zhang et al., 2000; Zhang et al., 2001; 
Zhang et al., 2002; Zhang et al., 2003; Zhang et al., 2004). Upstream inhibitory domain (ERE-DR Motif) that bind orphan receptors EAR2 
and EAR3, inhibitory and TR4, stimulatory (arrows). B-II, Histone deacetylase inhibitor (TSA)-induced LHR transcriptional activation 
through chromatin changes cause release of cell specific phosphatases (PP1, PP2A) (Zhang et al 2008). This permits phosphorylation of 
Sp1 at S641 via PI3K/PKCzeta (Zhang, 2006), and the release of repressor p107 and corepressor HDAC/mSin3A (Zhang et al., 2008; 
Dufau et al., 2010). Recruitment of Positive Coactivator4 PC4 induced by changes in chromatin structure is required for transcriptional 
activation that follows recruitment of TFIIB and Pol II (Liao et al., 2008; Liao et al., 2011). PC4 might function as a linker to bridge Sp1 to 
PIC through a not-yet identified protein(s) (red circle). Triangle: multiple transcriptional start sites. PA: polyadenylation sites. Open arrow, 





The cDNA for the human LHR encodes 699 amino 
acids (Minegishi et al., 1990; Jia et al., 1991).  
The receptor is composed of two functional units: the
extracellular hormone-binding domain and the seven-
membrane transmembrane/cytoplasmic module, which 
is the anchoring unit that transduces the signal initiated 
in the extracellular domain and couples to G proteins. 
The large extracellular  
domain binds LH and hCG with high affinity. 
Expression 
LHR is predominantly expressed in gonads.  
The LHR has also been identified in several non-
gonadal tissues (review, Rao, 2001), including human 
nonpregnant uterus, placenta (Reshef et al., 1990), 
fallopian tubes (Lei et al., 1993), uterine vessels, (Toth 
et al., 1994), umbilical cord (Rao et al., 1993), brain 
(Lei et al., 1993), breast (Meduri et al., 1997; Carlson 
et al., 2004), and adrenal gland (Lehmann et al., 1975). 
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Schematic representation of human LHR variants, as deduced from the alternative splicing of the transc ripts.  Arrow-head: LQ 
insertion. Exon 6A resides in intron 6, transcripts are terminated by a poly A tail (terminal) or via internal splice sites to produce a 150 bp 
(short) or 207 bp (long) internal exon and continue to exon 7-11 (Kossack et al., 2008). In all cases a truncated LHR protein of 209 aa is 
generated. Arrow: Stop codon. 
 
Localisation 
Predominantly localized in the cell membrane. 
Function 
The LHR mediates gonadotropin signaling and triggers 
intracellular responses that participate in gonadal 
maturation and function, as well as in the regulation of 
steroidogenesis and gametogenesis (review, Richards et 
al., 1988; Dufau, 1998; Dufau and Tsai-Morris, 2007). 
Luteinizing hormone through its surface receptors on 
the Leydig cell maintains general metabolic processes 
and steroidogenic enzymes to regulate the production 
of androgens. In the ovary, LH promotes follicular 
development, at stages beyond early antral follicles 
including the formation of preovulatory follicles and 
corpora lutea. Target disruption of LH receptor in the 
mouse revealed a normal prenatal development and 
lack of postnatal sexual development (Lei et al., 2001; 
Zhang et al., 2001). This indicated that LH/LHR action 
in male rodents is not required or can be compensatd 
by other hormone(s) or factors during fetal life which is 
in sharp contrast with the situation in the human. The 
major changes in sexual development observed after 
birth in the mouse included significant inhibition of
testis growth and descent and of sex accessory organs. 
Testosterone could partially restore spermatogenesis 
and fertility (Pakarainen et al., 2005; Yuan et al., 2006). 
Homology 
The percent identity below represents identity using 
Global pairwise alignment function (GAP). 
M. musculus: 83,2 
R. Norvegicus: 85,2 
D. Melanogaster: 40,1 
A. gambiae: 39,7 
C. elegans: 30,7 
Mutations 
Note 
Polymorphisms were detected in exon 1, 4, 8, 10 and 
11. Nucleotides insertion / deletion, single nucleotide 
mutation were detected in exons 1, 5, 7, 8, 10 and 11.  
Deletions of exon 8 or 9 or 10 (splice variants) were 
also detected (See reviews Themmen and Huhtaniemi, 
2000; Dufau and Tsai-Morris, 2007 and Segaloff, 
2009).  
Mutations were also found in the unique cryptic exon 
6A (Kossack et al., 2008). 
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EC: Extracellular domain. TM: Transmembrane domain. IC: Intracellular domain. Triangle box: the putative signal peptide. Vertical lines 
indicate exons. Normal amino acid residue (white circle). X: Stop. Activating mutations noted as green in familial male precocious puberty 
(FMPP)-autosomal dominant and/or sporadic male-limited precocious puberty (SMPP) or other; inactivating mutations in Leydig cells 
hypoplasia (LCH) noted in yellow. Polymorphism noted in blue. Underlined: N-glycosylation sites. 
 
Polymorphism: Without a known effect- missense 
mutation: R124Q, N291S, N312S. Silent mutation: 
L204, D355. 
Activating mutations: Most of these mutations are 
located in the sixth TM domain (TM6) and C terminal 
region of the third intracellular loop. Mutations also 
occur in other transmembrane helices except TM4 and 
TM7 (see figure). TM1: L368P, A373V; TM2: M398T; 
TM3: L457R; TM5: I542L; ICL3: D564G, A568V; 
TM6: M571I, A572V, I575L, T577I, D578G/Y/H/E, 
C581R. TM: transmembrane., ICL: intracellular loop. 
Inactivating mutations: I114F, C131R, V144F, F194V, 
C343S, E354K, I374T, T392I, W491X, L502P, C543R, 
C545X, R554X, A589X, A593P, Y612X, S616Y and 
I625K. Deletion - ∆L608/V609, aa 203-227 (exon 8), 
aa 228-289 (exon 9), aa 290-316 (exon 10), ∆Y317-
S324 (exon 11). Insertion: aa18 - LLKLLLLLQLQ. A 
cryptic exon 6A (resides in intron 6) with mutations  
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(A557C or G558C). 
Implicated in 
Disease 
Review: Themmen and Huhtaniemi, 2000; Dufau and 
Tsai-Morris, 2007; Segaloff, 2009. Refer to these 
reviews for individual mutations. 
Breast cancer 
Note 
The 18LQ insertion associated with adverse outcome in 
breast cancer patients could result from estrogen 
exposure in female carriers via increased LHR activity 
(Powell et al., 2003; Piersma et al., 2006). 
Prognosis 
Mutations may be linked to breast cancer prognosis. 
Familial male precocious puberty 
(FMPP) and sporadic male-limited 
precocious puberty (SMPP) 
Note 
FMPP is a gonadotropin independent precocious 
puberty, also known as testotoxicosis characterized by 
premature Leydig cell differentiation, hyperplasia and 
early spermatogenesis. It presents a clinical phenotype 
in the heterozygous form of LHR activating mutations. 
Signs of puberty are found at 1 to 4 yr old of age with 
elevated androgen production due to LHR mutations in 
transmembranes 1, 2, 3, 5 and 6 (see mutation section-
activating mutation). Those mutants are constitutively 
active. Mutations cause elevated basal levels of cAMP 
compared to WT in cells transfected with mutated LHR 
construct. A similar phenotype is observed in sporadic 
cases of this disorder. Association of FMPP and SMPP 
with development of testicular tumors are due to a 
missense mutation (D578G) which is the most common 
form of the condition in USA. Somatic mutation of the 
LHR (D578H) was found in the patients with Leydig 
cell adenoma and no history of FMPP. 
Male pseudohermaphroditism or Leydig 
cell hypoplasia (LCH) with various 
degree of hypogonadism severity 
Note 
There are two types of LCH associated with 
inactivating mutation of LHR. Clinical phenotype 
expressed in homozygous (most cases) or compound 
heterozygous (few cases) is caused by deletion, 
insertion, truncation or missense mutation (see 
mutation section) in extracellular or transmembrane 
regions of the LHR. Also, a genomic defect with 
mutation in the cryptic exon 6A (residing in the intron 
6) could lead to LCH. Type I LCH with 46XY disorder 
of sex development reveals a complete disruption of 
LH/hCG signaling in male patients characterized by a 
female external phenotype with a blind-ending vagin 
and cryptochidism. Type II LCH is characterized by 
reduced response to LH/hCG signaling, micropenis 
and/or hypospadias. 46XX siblings (carrying similar 
inactivating mutation of LHR) of affected 46XY 
individuals are infertile with normal female external 
genitalia but enlarged cystic ovaries and primary o 
secondary amenorrhea. Elevated serum LH is shown in 
both genders of patients. The underlining mechanism of 
the LCH caused by inactivating mutation of LHR might 
be associated with misfolding, reduced LH/hCG 
binding affinity and/or intracellular retention of the 
mutant LHR. 
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